已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

免疫疗法 免疫系统 细胞毒性T细胞 抗原 癌症免疫疗法 免疫学 获得性免疫系统 CD8型 抗体 先天免疫系统 医学 肿瘤抗原 T细胞 生物 癌症研究 免疫检查点 体外 生物化学
作者
Kelly D. Moynihan,Cary F. Opel,Gregory L. Szeto,Alice Tzeng,Eric Zhu,J Engreitz,Christina Williamson,Kavya Rakhra,Michael H. Zhang,Adrienne M. Rothschilds,Sudha Kumari,Ryan L. Kelly,Byron H. Kwan,Wuhbet Abraham,Kevin Hu,Naveen K. Mehta,Monique J. Kauke,Heikyung Suh,Jennifer R. Cochran,Douglas A. Lauffenburger
出处
期刊:Nature Medicine [Nature Portfolio]
卷期号:22 (12): 1402-1410 被引量:536
标识
DOI:10.1038/nm.4200
摘要

An immunotherapy consisting of a tumor-antigen targeting antibody, PD-1 blocking antibody, extended half-life recombinant IL-2 and a lymph-node-targeted T cell vaccine mobilized innate and adaptive immunity and eradicated large established tumors in a variety of mouse models. Checkpoint blockade with antibodies specific for cytotoxic T lymphocyte–associated protein (CTLA)-4 or programmed cell death 1 (PDCD1; also known as PD-1) elicits durable tumor regression in metastatic cancer, but these dramatic responses are confined to a minority of patients. This suboptimal outcome is probably due in part to the complex network of immunosuppressive pathways present in advanced tumors, which are unlikely to be overcome by intervention at a single signaling checkpoint. Here we describe a combination immunotherapy that recruits a variety of innate and adaptive immune cells to eliminate large tumor burdens in syngeneic tumor models and a genetically engineered mouse model of melanoma; to our knowledge tumors of this size have not previously been curable by treatments relying on endogenous immunity. Maximal antitumor efficacy required four components: a tumor-antigen-targeting antibody, a recombinant interleukin-2 with an extended half-life, anti-PD-1 and a powerful T cell vaccine. Depletion experiments revealed that CD8+ T cells, cross-presenting dendritic cells and several other innate immune cell subsets were required for tumor regression. Effective treatment induced infiltration of immune cells and production of inflammatory cytokines in the tumor, enhanced antibody-mediated tumor antigen uptake and promoted antigen spreading. These results demonstrate the capacity of an elicited endogenous immune response to destroy large, established tumors and elucidate essential characteristics of combination immunotherapies that are capable of curing a majority of tumors in experimental settings typically viewed as intractable.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
baiyeok发布了新的文献求助10
1秒前
Francisco2333完成签到,获得积分10
2秒前
2秒前
大模型应助何土旦采纳,获得10
2秒前
暮光之城发布了新的文献求助10
3秒前
4秒前
4秒前
王抗抗完成签到 ,获得积分10
5秒前
5秒前
就这发布了新的文献求助10
7秒前
周树人完成签到,获得积分10
7秒前
8秒前
OK应助科研通管家采纳,获得10
8秒前
luoyan应助科研通管家采纳,获得10
8秒前
乐乐应助科研通管家采纳,获得10
8秒前
9秒前
9秒前
大模型应助科研通管家采纳,获得10
9秒前
OK应助科研通管家采纳,获得10
9秒前
Li完成签到,获得积分10
11秒前
大个应助邪恶五角星采纳,获得10
12秒前
科目三应助星星采纳,获得10
13秒前
MissZhang完成签到,获得积分10
15秒前
16秒前
wenwenwang完成签到 ,获得积分10
17秒前
JJ完成签到 ,获得积分10
21秒前
zfcaabbcc完成签到,获得积分10
22秒前
刘海英完成签到 ,获得积分10
26秒前
26秒前
ding应助zz采纳,获得10
27秒前
qlingjun完成签到 ,获得积分10
28秒前
Blue发布了新的文献求助10
29秒前
反复发作完成签到 ,获得积分10
31秒前
幸福铸海完成签到 ,获得积分10
31秒前
华仔应助YaLanYan采纳,获得10
32秒前
淡定自中发布了新的文献求助10
33秒前
前行僧完成签到,获得积分10
38秒前
40秒前
XQQDD发布了新的文献求助10
40秒前
Chan完成签到,获得积分10
44秒前
高分求助中
Clinical Epidemiology: The Essentials, 6e 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Graphene Handbook (2019 Edition) 800
Adhesion Science: Principles & Practice 800
Signals, Systems, and Signal Processing 610
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
The Immune System (Fifth Edition) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6569560
求助须知:如何正确求助?哪些是违规求助? 8348682
关于积分的说明 17886434
捐赠科研通 5697611
什么是DOI,文献DOI怎么找? 2944520
邀请新用户注册赠送积分活动 1920404
关于科研通互助平台的介绍 1797247